The US Supreme Court has today dealt a blow to the worldwide biotech industry by declaring that inventions deriving from isolated human DNA cannot be patented. Find out a little more about the situation by downloading this white paper straight from our Pharma IQ!
The CRISPR tool has attracted worldwide attention from the R&D industry in regards to its capabilities for gene editing. CRISPR alongside the use of the Cas9 protein enables the ability to target...
Curious to see who will be joining you at the 1st annual CRISPR - A New Era in Gene Editing summit? Check out our anticipated attendee list to see who will potentially be joining us!
The timeline spans from 2011 and the discovery of a second RNA to recent advancements in 2016, outlining the major experiments that took place to lead CRISPR to where it is today.
Our Pharma IQ content team put together this great informational interview about the emerging technologies that is CRISPR and CAS9. Check out all the information you need to know!
Having trouble convincing your boss for the time off? Download our Convince Your Boss Letter for extra support!
The money being spent in gene editing is going straight towards CRISPR, but which big Pharma companies are spending and what are they spending their money on? We know that millions are being poured into this dynamic research, but this infographic will tell you where and how!
We spoke to Patrick Ansems, EMEAI, Director at PerkinElmer who said "Biology is a strategic area for us as big data analytics can play an important role in unlocking insights from complex biological data. For example, if you look at transitional science, it's all about aggregating the data together to understand the disease."